

# Joan Tosca-Cuquerella

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7783508/publications.pdf>

Version: 2024-02-01

50  
papers

637  
citations

687363

13  
h-index

610901

24  
g-index

51  
all docs

51  
docs citations

51  
times ranked

1096  
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives. <i>Gastroenterology</i> Y <i>Hepatology</i> , 2022, 45, 383-389.	0.5	2
2	Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. <i>Scientific Reports</i> , 2022, 12, 2463.	3.3	7
3	Caustic ingestion: development and validation of a prognostic score. <i>Endoscopy</i> , 2021, 53, 784-791.	1.8	6
4	Multi-omic analysis unveils biological pathways in peripheral immune system associated to minimal hepatic encephalopathy appearance in cirrhotic patients. <i>Scientific Reports</i> , 2021, 11, 1907.	3.3	9
5	Patients with Minimal Hepatic Encephalopathy Show Altered Thermal Sensitivity and Autonomic Function. <i>Journal of Clinical Medicine</i> , 2021, 10, 239.	2.4	6
6	Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1277-1288.	3.7	16
7	A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2806.	2.4	11
8	NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved. <i>Cells</i> , 2021, 10, 1687.	4.1	21
9	Transjugular intrahepatic portosystemic shunt reduces hospital care burden in patients with decompensated cirrhosis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1519-1527.	2.0	3
10	Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1021-1029.	3.7	8
11	Clinical assessment of risk factors for infection in inflammatory bowel disease patients. <i>International Journal of Colorectal Disease</i> , 2020, 35, 491-500.	2.2	8
12	Motor and Cognitive Performance in Patients with Liver Cirrhosis with Minimal Hepatic Encephalopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2154.	2.4	13
13	Oxidative and Nitrosative Pattern in Circulating Leukocytes of Very Early/Early Hepatocellular Carcinoma Patients. <i>Anticancer Research</i> , 2020, 40, 6853-6861.	1.1	4
14	Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study. <i>United European Gastroenterology Journal</i> , 2019, 7, 1042-1050.	3.8	12
15	Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy. <i>Journal of Translational Medicine</i> , 2019, 17, 293.	4.4	16
16	Association of elevated serum triglyceride levels with a more severe course of acute pancreatitis: Cohort analysis of 1457 patients. <i>Pancreatology</i> , 2019, 19, 623-629.	1.1	48
17	FRI-118-Decreased cognitive performance is associated with reduced resting state connectivity and gray matter atrophy in patients with minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2019, 70, e439.	3.7	0
18	SAT-085-Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2019, 70, e665.	3.7	0

#	ARTICLE	IF	CITATIONS
19	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1492-1500.	1.3	37
20	Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1053-1059.	2.2	6
21	P: 55â€fDecreased Cognitive Performance Is Associated With Reduced Resting State Connectivity and Gray Matter Atrophy in Patients With Minimal Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2019, 114, S27-S28.	0.4	0
22	Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, caseâ€control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 605-614.	3.7	57
23	Cirrhotic patients with minimal hepatic encephalopathy have increased capacity to eliminate superoxide and peroxynitrite in lymphocytes, associated with cognitive impairment. <i>Free Radical Research</i> , 2018, 52, 118-133.	3.3	4
24	HLA-DQ: Celiac disease vs inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2018, 24, 96-103.	3.3	16
25	Learning and Memory Impairments in Patients with Minimal Hepatic Encephalopathy are Associated with Structural and Functional Connectivity Alterations in Hippocampus. <i>Scientific Reports</i> , 2018, 8, 9664.	3.3	28
26	Effect of Serum Triglyceride Levels on the Progress of Acute Pancreatitis. <i>Gastroenterology</i> , 2017, 152, S281-S282.	1.3	0
27	Disease severity and treatment requirements in familial inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2017, 32, 1197-1205.	2.2	5
28	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 120-131.	0.4	93
29	Minimal hepatic encephalopathy is associated with increased capacity to eliminate superoxide and peroxynitrite in lymphocytes. <i>Journal of Hepatology</i> , 2017, 66, S143.	3.7	0
30	HLA-DQ: Celiac Disease Versus Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 152, S977-S978.	1.3	0
31	Caustic Ingestion: Development and Validation of a Prognostic Score. <i>Gastroenterology</i> , 2017, 152, S891.	1.3	0
32	Phenotypic Characteristics can Predict the Need of Adjuvant Therapy in Addition to Aminosalicylates for Maintenance of Remission in Ulcerative Colitis. <i>Gastroenterology</i> , 2017, 152, S753.	1.3	0
33	Minimal hepatic encephalopathy is associated with expansion and activation of CD4+CD28â”, Th22 and Tfh and B lymphocytes. <i>Scientific Reports</i> , 2017, 7, 6683.	3.3	30
34	P327 Evolution after a âœde-intensificationâ strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S243-S243.	1.3	2
35	Reduced resting state connectivity and gray matter volume correlate with cognitive impairment in minimal hepatic encephalopathy. <i>PLoS ONE</i> , 2017, 12, e0186463.	2.5	22
36	Tu1926 Evolution After Anti-TNF Drug Discontinuation in Patients With Inflammatory Bowel Disease (IBD): A Multicenter Long-Term Follow-Up Study. <i>Gastroenterology</i> , 2016, 150, S979.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Amyloidosis in Inflammatory Bowel Disease: A Systematic Review of Epidemiology, Clinical Features, and Treatment. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1245-1253.	1.3	26
38	Sa1910 Family Association In Inflammatory Bowel Disease And Its Treatment Requirements. <i>Gastroenterology</i> , 2016, 150, S400.	1.3	0
39	Pathogenesis of Crohn's disease: Bug or no bug. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2015, 6, 1.	1.0	33
40	Could HLA-DQ Suggest Why Some Patients Have Olmesartan-Related Diarrhea and Others Don't?. <i>American Journal of Gastroenterology</i> , 2015, 110, 1507-1508.	0.4	8
41	Sa1129 Fecal Incontinence (FI) in Patients With Inflammatory Bowel Disease (IBD). Probably As Important As Prevalent. <i>Gastroenterology</i> , 2014, 146, S-207.	1.3	2
42	Su1189 There Is a Different Tissue Transglutaminase (tTG) Distribution in Celiac Disease (CD) and Inflammatory Bowel Disease (IBD) Duodenal Mucosa. <i>Gastroenterology</i> , 2013, 144, S-422-S-423.	1.3	0
43	W1255 Is Celiac Disease Genetic Predisposition Related to Fructose or Lactose Malabsorption in Inflammatory Bowel Disease (IBD) Patients?. <i>Gastroenterology</i> , 2010, 138, S-684.	1.3	0
44	S1097 Weekend Effect on Patients With a Nonvariceal Upper Gastrointestinal Hemorrhage (NVUGIH): Experience in a Single Teaching Hospital. <i>Gastroenterology</i> , 2010, 138, S-178-S-179.	1.3	0
45	S1183 HLA Predisposing for Celiac Disease (HLA Dq2 and Dq8) Is Less Frequent in Inflammatory Bowel Disease (IBD) Patients. Preliminary Results. <i>Gastroenterology</i> , 2009, 136, A-208.	1.3	1
46	T1292 Association Between Early Transient Versus Persistent Organ Failure, Local Complications and Outcome in Acute Pancreatitis. <i>Gastroenterology</i> , 2009, 136, A-541.	1.3	1
47	Alteraciones motoras del intestino delgado. Síndrome de pseudoobstrucción intestinal. <i>Medicine</i> , 2008, 10, 341-348.	0.0	0
48	Manejo general y extrahospitalario de los pacientes con patología motora intestinal. <i>Medicine</i> , 2008, 10, 379-383.	0.0	0
49	Factors predicting poor prognosis in ischemic colitis. <i>World Journal of Gastroenterology</i> , 2006, 12, 4875-8.	3.3	52
50	Clinical evaluation of drug-induced hepatitis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2005, 97, 258-65.	0.3	12